2. Others Apoptosis
  3. Drug Derivative Apoptosis Bcl-2 Family
  4. Secoxyloganin

Secoxyloganin is an orally effective iridoid derivative. Secoxyloganin can be isolated from the flower buds of L. japonica. Secoxyloganin induces Apoptosis by inhibiting the expression of Bcl-2. Secoxyloganin potently inhibits the proliferation of breast cancer cells, while exerting weak activity against normal mammary epithelial cells. Secoxyloganin inhibits the decrease in tail vein blood flow associated with allergic reactions.

Para uso exclusivo en investigación. No vendemos a pacientes.

Secoxyloganin

Secoxyloganin Estructura química

No. CAS : 58822-47-2

Tamaño Precio Stock Cantidad
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 En stock
Solution
10 mM * 1 mL in DMSO En stock
Solid
5 mg En stock
10 mg En stock
20 mg En stock
50 mg   Obtener un presupuesto  
100 mg   Obtener un presupuesto  

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 1 publication(s) in Google Scholar

Other Forms of Secoxyloganin:

Secoxyloganin Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Secoxyloganin

Ver todos los productos específicos de isoformas Bcl-2 Family:

Ver todas las isoformas
Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim BNIP3 Bad

  • Actividad biológica

  • Pureza y Documentación

  • Referencias

  • Revisión del cliente

Descripciòn

Secoxyloganin is an orally effective iridoid derivative. Secoxyloganin can be isolated from the flower buds of L. japonica. Secoxyloganin induces Apoptosis by inhibiting the expression of Bcl-2. Secoxyloganin potently inhibits the proliferation of breast cancer cells, while exerting weak activity against normal mammary epithelial cells. Secoxyloganin inhibits the decrease in tail vein blood flow associated with allergic reactions[1][2].

IC50 & Target[1]

Bcl-2

 

In Vitro

Secoxyloganin (0.37-96 µM; 24 h) potently inhibits the proliferation of breast cancer MDA-MB-231 cells with an IC50 of 6.5 µM, while it shows weak activity against normal fR2 mammary epithelial cells with an IC50 of 38 µM[1].
Secoxyloganin (6-24 µM) induces concentration-dependent DNA damage in breast cancer MDA-MB-231 cells[1].
Secoxyloganin (6-24 µM; 24 h) induces concentration-dependent apoptosis in breast cancer MDA-MB-231 cells[1].
Secoxyloganin (6-24 µM; 24 h) regulates the expression of apoptosis-related proteins in human breast cancer MDA-MB-231 cells, upregulating Bax and decreasing Bcl-2[1].
Secoxyloganin (6-24 µM) induces G0/G1 cell cycle arrest in breast cancer MDA-MB-231 cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Secoxyloganin Related Antibodies

Apoptosis Analysis[1]

Cell Line: human breast cancer MDA-MB-231 cells
Concentration: 6-24 µM
Incubation Time: 24 h
Result: Induced a concentration-dependent increase in apoptosis in MDA-MB-231 cells, with increased intensities of early apoptotic yellow-green fluorescence and late apoptotic orange-red fluorescence at higher concentrations.
Increased the percentage of apoptotic MDA-MB-231 cells from 3.7% in control to 21.8% at 6 µM, 30.3% at 12 µM, and 40.2% at 24 µM.

Cell Cycle Analysis[1]

Cell Line: human breast cancer MDA-MB-231 cells
Concentration: 6-24 µM
Incubation Time: Certain time
Result: Increased the proportion of MDA-MB-231 cells in the G0/G1 phase from 32.76% in control to 43.61% at 6 µM, 69.79% at 12 µM, and 77.50% at 24 µM, indicating G0/G1 cell cycle arrest.
In Vivo

Secoxyloganin (10 mg/kg; p.o.; administered on days 0, 3, 6, and 9) significantly inhibits the decrease in tail vein blood flow in lysozyme-sensitized mice without affecting platelet aggregation[2].\n


MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: ddY mice (male, 5 weeks old, SPF grade, sensitized intraperitoneally with HEL in complete Freund’s adjuvant)[2]
Dosage: 10 mg/kg
Administration: p.o.; 4 doses on days 0, 3, 6, 9
Result: Significantly inhibited the HEL-induced decrease in tail vein BF compared to the HEL-sensitized control group after day 7 of sensitization, with BF remaining near 100% of normal levels through day 9 (control BF dropped to ~70% of normal).
Showed no inhibitory effect on ADP-induced whole blood platelet aggregation in HEL-sensitized mice on day 9.
Peso molecular

404.37

Fòrmula

C17H24O11
No. CAS
Appearance

Solid

Color

White to light yellow

SMILES

C=C[C@@H]1[C@@H](C(C(OC)=O)=CO[C@@]1([H])O[C@@H]2O[C@@H]([C@@H](O)[C@H](O)[C@H]2O)CO)CC(O)=O
Structure Classification
Initial Source
Envío

Room temperature in continental US; may vary elsewhere.
Almacenamiento

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvente y solubilidad
In Vitro: 

DMSO : 100 mg/mL (247.30 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.4730 mL 12.3649 mL 24.7298 mL
5 mM 0.4946 mL 2.4730 mL 4.9460 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Calculadora de molaridad

  • Calculadora de dilución

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (6.18 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (6.18 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
Referencias

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.4730 mL 12.3649 mL 24.7298 mL 61.8246 mL
5 mM 0.4946 mL 2.4730 mL 4.9460 mL 12.3649 mL
10 mM 0.2473 mL 1.2365 mL 2.4730 mL 6.1825 mL
15 mM 0.1649 mL 0.8243 mL 1.6487 mL 4.1216 mL
20 mM 0.1236 mL 0.6182 mL 1.2365 mL 3.0912 mL
25 mM 0.0989 mL 0.4946 mL 0.9892 mL 2.4730 mL
30 mM 0.0824 mL 0.4122 mL 0.8243 mL 2.0608 mL
40 mM 0.0618 mL 0.3091 mL 0.6182 mL 1.5456 mL
50 mM 0.0495 mL 0.2473 mL 0.4946 mL 1.2365 mL
60 mM 0.0412 mL 0.2061 mL 0.4122 mL 1.0304 mL
80 mM 0.0309 mL 0.1546 mL 0.3091 mL 0.7728 mL
100 mM 0.0247 mL 0.1236 mL 0.2473 mL 0.6182 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Secoxyloganin Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Secoxyloganin58822-47-2Drug DerivativeApoptosisBcl-2 FamilyDrug derivativeBcl-2apoptosisfR2 breast epithelial cellsbreast cancercyclin D2MDA-MB-231 cellsG0/G1 cell cycle arrestallergyDNA damagenormal breast epithelial cellsInhibitorinhibitorinhibit

Productos vistos recientemente:

Consulta en línea

Your information is safe with us. * Required Fields.

Nombre del producto

  

Requested Quantity *

Nombre del solicitante *

 

Saludo

Direcciòn del E-mail *

 

Número de teléfono *

Department

 

Nombre de la Organizaciòn *

City

Provincia

Country or Region *

      

Observaciones

Consulta para venta a granel

Inquiry Information

Nombre del producto:
Secoxyloganin
Cat. No.:
HY-N3009
Cantidad:
MCE Japan Authorized Agent:

Revisión del cliente

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Nombre del producto

  

Lot #

Nombre del solicitante *

 

Direcciòn del E-mail *

Número de teléfono

 

Department *

Nombre de la Organizaciòn *

 

Country or Region *

Observaciones

SAFETY DATA SHEET (SDS)

English - EN (394 KB) Français - FR (394 KB) Deutsch - DE (394 KB) Norwegian - NO (394 KB) Español - ES (394 KB) Swedish - SV (394 KB) Italian - IT (394 KB) Korean - KR (394 KB) Portuguese - PT (394 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.